---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-007143"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:23:07.723094+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera cuts Ameluz transfer price to 25%, raises up to $16M in private placement

## Summary
- Transfer price reduced from 50% to 25% for 2024-2025; stepwise increases to max 35% from 2032; minimum dollar amount per unit.
- Company to assume control of all US clinical trials for Ameluz by June 1, 2024, improving cost management and oversight.
- Private placement led by Rosalind Advisors: $8M from Series B-1 Preferred, plus $8M warrants tied to milestones; up to $16M gross.
- Conversion price set at $0.7074 per share; Series B-3 conversion requires shareholder approval to increase authorized shares.
- Net proceeds to fund general operations and accelerate development of additional Ameluz indications (BCC, SCC, acne).

## SEC filing metadata
- accession: 0001493152-24-007143
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/0001493152-24-007143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-007143
- JSON: https://secwatch.observer/filing/0001493152-24-007143.json
- Plain text: https://secwatch.observer/filing/0001493152-24-007143.txt

## Key facts
- Material Agreements
  Biofrontera Inc. entered into Second Amended and Restated License and Supply Agreement with Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH valued at Transfer price changed to 25% through 2025 then increasing up to 35% starting in 2032 (effective 2024-02-13).
  - Action: entry
  - Agreement: license
  - Counterparty: Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH
  - Value: Transfer price changed to 25% through 2025 then increasing up to 35% starting in 2032
  - Effective: 2024-02-13
  source text: On February 19, 2024, Biofrontera Inc. (the “ Company ”) entered into the Second Amended and Restated License and Supply Agreement (the “ LSA ”), effective as of February 13, 2024 , by and among the Company, Biofrontera Pharma GmbH (“ Pharma ”), and Biofrontera Bioscience GmbH (“ Bioscience ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/0001493152-24-007143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.